The closing price of Novavax, Inc. (NASDAQ: NVAX) was $5.29 for the day, up 6.22% from the previous closing price of $4.98. In other words, the price has increased by $+0.31 from its previous closing price. On the day, 8751787 shares were traded.
Ratios:
Our analysis of NVAX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.67 and its Current Ratio is at 0.70.
On April 20, 2023, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $55 to $10.
B. Riley Securities Downgraded its Buy to Neutral on March 01, 2023, whereas the target price for the stock was revised from $29 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 743.15M and an Enterprise Value of 403.73M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75. Its current Enterprise Value per Revenue stands at 0.73 whereas that against EBITDA is -0.83.
Stock Price History:
Over the past 52 weeks, NVAX has reached a high of $11.36, while it has fallen to a 52-week low of $3.53. The 50-Day Moving Average of the stock is 4.59, while the 200-Day Moving Average is calculated to be 6.47.
Shares Statistics:
NVAX traded an average of 9.44M shares per day over the past three months and 7.36M shares per day over the past ten days. A total of 139.51M shares are outstanding, with a floating share count of 131.81M. Insiders hold about 5.81% of the company’s shares, while institutions hold 55.74% stake in the company. Shares short for NVAX as of Feb 29, 2024 were 52.74M with a Short Ratio of 5.58, compared to 52.09M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 37.68% and a Short% of Float of 43.92%.
Earnings Estimates
The firm’s stock currently is rated by 4 analysts. On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.34 and a low estimate of -$1.48, while EPS last year was -$3.41. The consensus estimate for the next quarter is -$1.1, with high estimates of -$0.53 and low estimates of -$1.93.
Analysts are recommending an EPS of between $0.13 and -$1.85 for the fiscal current year, implying an average EPS of -$0.91. EPS for the following year is $0.2, with 6 analysts recommending between $2.72 and -$0.82.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $102M to a low estimate of $99.8M. As of the current estimate, Novavax, Inc.’s year-ago sales were $80.95M, an estimated increase of 24.30% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $941.8M, while the lowest revenue estimate was $800M, resulting in an average revenue estimate of $852.49M. In the same quarter a year ago, actual revenue was $983.71M, down -13.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $951.72M in the next fiscal year. The high estimate is $1.26B and the low estimate is $770M. The average revenue growth estimate for next year is up 11.60% from the average revenue estimate for this year.
